Chaudhry, MamoonahAlessandrini, MarcoRademan, JacobusDodgen, Tyren MarkSteffens, Francois E.Van Zyl, Danie G.Gaedigk, AndreaPepper, Michael Sean2018-01-162018-01-162017-03Chaudhry, M., Alessandrini, M., Rademan, J. et al. 2017, 'Impact of CYP2D6 genotype on amitriptyline efficacy for the treatment of diabetic peripheral neuropathy : a pilot study ', Pharmacogenomics, vol. 18, no. 5, pp. 433-443.1462-2416 (print)1744-8042 (online)10.2217/pgs-2016-0185http://hdl.handle.net/2263/63560AIM : Therapy with low-dose amitriptyline is commonly used to treat painful diabetic peripheral neuropathy. There is a knowledge gap, however, regarding the role of variable CYP2D6-mediated drug metabolism and side effects (SEs). We aimed to generate pilot data to demonstrate that SEs are more frequent in patients with variant CYP2D6 alleles. METHOD : To that end, 31 randomly recruited participants were treated with low-dose amitriptyline for painful diabetic peripheral neuropathy and their CYP2D6 gene sequenced. RESULTS : Patients with predicted normal or ultra-rapid metabolizer phenotypes presented with less SEs compared with individuals with decreased CYP2D6 activity. CONCLUSION : Hence, CYP2D6 genotype contributes to treatment outcome and may be useful for guiding drug therapy. Future investigations in a larger patient population are planned to support these preliminary findings.enThis  work  is  licensed  under  the  Attribution-NonCommercial-NoDerivatives  4.0  Unported  License. Activity scoreAdverse drug reactionsAmitriptylineCYP2D6Diabetic neuropathyPharmacogeneticsDemethylationIndomethacinManagementRatsPainArticle